{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:35:59Z","timestamp":1762551359936,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009479","name":"Royal Society of Arts and Sciences in Gothenburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006726","name":"R\u00e5dman och Fru Ernst Collianders Stiftelse f\u00f6r V\u00e4lg\u00f6rande \u00c4ndam\u00e5l","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006726","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003745","name":"Wilhelm och Martina Lundgrens Stiftelser","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003745","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["autonomicneuroscience.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autonomic Neuroscience"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.autneu.2025.103253","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T19:19:45Z","timestamp":1739819985000},"page":"103253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Monotherapy with tolterodine or mirabegron is insufficient for ameliorating cyclophosphamide-induced bladder overactivity in rats"],"prefix":"10.1016","volume":"258","author":[{"given":"H\u00e5vard","family":"Fjelltveit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozgu","family":"Aydogdu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhavik","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2527-4713","authenticated-orcid":false,"given":"Michael","family":"Winder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.autneu.2025.103253_bb0005","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1177\/1756287218801282","article-title":"Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience","volume":"10","author":"Allison","year":"2018","journal-title":"Ther. Adv. Urol."},{"issue":"7","key":"10.1016\/j.autneu.2025.103253_bb0010","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1038\/bjp.2008.6","article-title":"Cholinergic nitric oxide release from the urinary bladder mucosa in cyclophosphamide-induced cystitis of the anaesthetized rat","volume":"153","author":"Andersson","year":"2008","journal-title":"Br. J. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.autneu.2025.103253_bb0015","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.autneu.2010.08.008","article-title":"Pharmacological modulation of the micturition pattern in normal and cyclophosphamide pre-treated conscious rats","volume":"159","author":"Andersson","year":"2011","journal-title":"Auton. Neurosci."},{"issue":"1\u20132","key":"10.1016\/j.autneu.2025.103253_bb0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.autneu.2012.06.004","article-title":"Muscarinic receptor subtypes involved in urothelium-derived relaxatory effects in the inflamed rat urinary bladder","volume":"170","author":"Andersson","year":"2012","journal-title":"Auton. Neurosci."},{"issue":"8","key":"10.1016\/j.autneu.2025.103253_bb0025","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/1756287218781255","article-title":"The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy","volume":"10","author":"Andersson","year":"2018","journal-title":"Ther. Adv. Urol."},{"issue":"2","key":"10.1016\/j.autneu.2025.103253_bb0030","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/PL00007094","article-title":"Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine","volume":"19","author":"Appell","year":"2001","journal-title":"World. J. Urol."},{"issue":"4","key":"10.1016\/j.autneu.2025.103253_bb0035","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/pros.24101","article-title":"Prostate-to-bladder cross-sensitization in a model of zymosan-induced chronic pelvic pain syndrome in rats","volume":"81","author":"Aydogdu","year":"2021","journal-title":"Prostate"},{"issue":"9","key":"10.1016\/j.autneu.2025.103253_bb0040","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1464-410X.2009.09036.x","article-title":"Patient-reported reasons for discontinuing overactive bladder medication","volume":"105","author":"Benner","year":"2010","journal-title":"BJU Int."},{"issue":"18","key":"10.1016\/j.autneu.2025.103253_bb0045","doi-asserted-by":"crossref","first-page":"8063","DOI":"10.1523\/JNEUROSCI.22-18-08063.2002","article-title":"Beta-adrenoceptor agonists stimulate endothelial nitric oxide synthase in rat urinary bladder urothelial cells","volume":"22","author":"Birder","year":"2002","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.autneu.2025.103253_bb0050","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/pros.22930","article-title":"The beta-3 adrenoceptor agonist, mirabegron relaxes isolated prostate from human and rabbit: new therapeutic indication?","volume":"75","author":"Calmasini","year":"2015","journal-title":"Prostate"},{"issue":"13","key":"10.1016\/j.autneu.2025.103253_bb0055","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1111\/bph.14669","article-title":"Influence of sildenafil on the purinergic components of nerve-mediated and urothelial ATP release from the bladder of normal and spinal cord injured mice","volume":"176","author":"Chakrabarty","year":"2019","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.autneu.2025.103253_bb0060","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.eururo.2012.10.048","article-title":"Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a \u03b2(3)-adrenoceptor agonist, in overactive bladder","volume":"63","author":"Chapple","year":"2013","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.autneu.2025.103253_bb0065","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/nau.22505","article-title":"Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability","volume":"33","author":"Chapple","year":"2014","journal-title":"Neurourol.Urodyn."},{"issue":"5","key":"10.1016\/j.autneu.2025.103253_bb0070","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/iju.13066","article-title":"Combination therapy with beta3 -adrenoceptor agonists and muscarinic acetylcholine receptor antagonists: efficacy in rats with bladder overactivity","volume":"23","author":"Furuta","year":"2016","journal-title":"Int. J. Urol."},{"issue":"13","key":"10.1016\/j.autneu.2025.103253_bb0075","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2165\/00002018-200427130-00005","article-title":"Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults","volume":"27","author":"Garely","year":"2004","journal-title":"Drug Saf."},{"issue":"4","key":"10.1016\/j.autneu.2025.103253_bb0080","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.eururo.2018.05.005","article-title":"Long-term safety and efficacy of Mirabegron and Solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre phase 3 study (SYNERGY II)","volume":"74","author":"Gratzke","year":"2018","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.autneu.2025.103253_bb0085","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/bju.13515","article-title":"Mirabegron causes relaxation of human and rat corpus cavernosum: could it be a potential therapy for erectile dysfunction?","volume":"118","author":"Gur","year":"2016","journal-title":"BJU Int."},{"issue":"4","key":"10.1016\/j.autneu.2025.103253_bb0090","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/bju.13882","article-title":"Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)","volume":"120","author":"Herschorn","year":"2017","journal-title":"BJU Int."},{"issue":"3","key":"10.1016\/j.autneu.2025.103253_bb0095","first-page":"935","article-title":"Mirabegron for overactive bladder: a novel, first-in-class \u03b23-agonist therapy","volume":"10","author":"Imran","year":"2013","journal-title":"Urol. J."},{"issue":"10","key":"10.1016\/j.autneu.2025.103253_bb0100","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/pros.23518","article-title":"Prostatic stromal inflammation is associated with bladder outlet obstruction in patients with benign prostatic hyperplasia","volume":"78","author":"Inamura","year":"2018","journal-title":"Prostate"},{"issue":"6","key":"10.1016\/j.autneu.2025.103253_bb0105","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S0302-2838(02)00177-X","article-title":"Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder","volume":"41","author":"Kreder","year":"2002","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.autneu.2025.103253_bb0110","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0090-4295(96)00423-2","article-title":"Elevated nitric oxide in the urinary bladder in infectious and noninfectious cystitis","volume":"48","author":"Lundberg","year":"1996","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.autneu.2025.103253_bb0115","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1464-410X.2006.06679.x","article-title":"The role of the urothelium in mediating bladder responses to isoprenaline","volume":"99","author":"Murakami","year":"2007","journal-title":"BJU Int."},{"issue":"4","key":"10.1016\/j.autneu.2025.103253_bb0120","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","article-title":"Results of a randomized phase III trial of mirabegron in patients with overactive bladder","volume":"189","author":"Nitti","year":"2013","journal-title":"J. Urol."},{"issue":"12","key":"10.1016\/j.autneu.2025.103253_bb0125","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1007\/s00345-021-03774-7","article-title":"Effects of beta3-adrenoceptor agonist on acute urinary retention in a rat model","volume":"39","author":"Noh","year":"2021","journal-title":"World. J. Urol."},{"issue":"1","key":"10.1016\/j.autneu.2025.103253_bb0130","doi-asserted-by":"crossref","first-page":"e00564","DOI":"10.1002\/prp2.564","article-title":"Combination drug therapy against OAB normalizes micturition parameters and increases the release of nitric oxide during chemically induced cystitis","volume":"8","author":"Patel","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"issue":"2","key":"10.1016\/j.autneu.2025.103253_bb0135","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.urology.2008.07.031","article-title":"Multiplex analysis of urinary cytokine levels in rat model of cyclophosphamide-induced cystitis","volume":"73","author":"Smaldone","year":"2009","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.autneu.2025.103253_bb0140","first-page":"247","article-title":"Involvement of nitric oxide in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis","volume":"150","author":"Souza-Fiho","year":"1997","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.autneu.2025.103253_bb0145","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pharmthera.2018.04.010","article-title":"Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder","volume":"189","author":"Yamada","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.autneu.2025.103253_bb0150","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/bju.12649","article-title":"Phase III, randomised, double-blind, placebo-controlled study of the \u03b23-adrenoceptor agonist mirabegron, 50mg once daily, in Japanese patients with overactive bladder","volume":"113","author":"Yamaguchi","year":"2014","journal-title":"BJU Int."}],"container-title":["Autonomic Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1566070225000153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1566070225000153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:32:53Z","timestamp":1762551173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1566070225000153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":30,"alternative-id":["S1566070225000153"],"URL":"https:\/\/doi.org\/10.1016\/j.autneu.2025.103253","relation":{},"ISSN":["1566-0702"],"issn-type":[{"type":"print","value":"1566-0702"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monotherapy with tolterodine or mirabegron is insufficient for ameliorating cyclophosphamide-induced bladder overactivity in rats","name":"articletitle","label":"Article Title"},{"value":"Autonomic Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autneu.2025.103253","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103253"}}